Login Register Cart 0
Generic placeholder image

Current Probiotics

Editor-in-Chief

ISSN (Print): 2666-6499
ISSN (Online): 2666-6502

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Quality by Design-based Formulation of Fizzy Granules Containing Probiotics

Author(s): Shubham Sharma, Sanyam Sharma, Subh Naman and Ashish Baldi*

Volume 2, 2025

Published on: 11 April, 2025

Article ID: e26666499346209 Pages: 20

DOI: 10.2174/0126666499346209250214075754

Price: $65

Abstract

Introduction: Probiotics have proven to have a strong potential for treating and/or preventing a wide range of diseases and also aid in maintaining a healthy gut microbial ecology and are effective against pathogens that are resistant to many drugs. As a result, the probiotics industry is expanding fast on a global scale, and research to explore probiotics into medicinal adjuvants has been intensified across the globe. However, due to the lack of an attractive dosage form, probiotics are not very compliant among patients. The present study aimed to formulate fizzy granules of probiotics (Lactobacillus sporogenes) by involving the concept of quality by design for industrial acceptance.

Methods: For this, critical formulation attributes and various risks involved during the formulation have been identified through the Ishikawa fishbone diagram and risk assessment studies in compliance with relevant ICH guidelines. Selected significant variables involved during the formulation were further analyzed through a central composite design to analyze the optimum level of variables. Further, 2D contour plots and 3D response surface plots have been designed to define the relationship between the quality attributes and input variables.

Results and Discussion: The developed statistical model was further validated and found appropriate to define the quality parameters at an acceptable level. Final quality profiling of the developed probiotics fizzy granules was performed to validate compliance with the quality target product profile and results were found to be satisfactory.

Conclusion: This study involved the development of a novel fizzy probiotic formulation, incorporating the concept of quality by design to enhance acceptance among patients, pharmaceutical companies, and regulatory bodies.

Keywords: Central composite design, formulation by design, fizzy granules, 2D contour plots, fizzy drinks, probiotics.

[1]
Lieberman, H.; Lachman, L.; Schwartz, J.B. Pharmaceutical Dosage Forms: Tablets; MARCEL DEKKER, INC: New York, 1989, Vol. 1, .
[2]
Douroumis, D. Orally disintegrating dosage forms and taste-masking technologies; 2010. Expert Opin. Drug Deliv., 2011, 8(5), 665-675.
[http://dx.doi.org/10.1517/17425247.2011.566553] [PMID: 21438776]
[3]
Srinath, K.R.; Chowdary, C.P.; Palanisamy, P.; Krishna, A.V.; Aparna, S. Formulation and evaluation of effervescent tablets of paracetamol. Int J Pharm Res Dev., 2011, 3(3), 76-104.
[4]
Diyya, A.; Thomas, N.V. Formulation and evaluation of Metronidazole effervescent granules. Int. J. Pharm. Sci. Res., 2018, 9(6), 2525-2529.
[5]
Masaad, AMA; Maghrabi, IA Formulation of a newly effervescent paracetamol tablets. 2017. Available from: https://www.semanticscholar.org/paper/Formulation-of-a-newly-effervescent-paracetamol-Masaad-Maghrabi/f23127b1daf25e10895ed281e1291bf7187c1bb8
[6]
Tekade, B.W.; Jadhao, U.T.; Thakare, V.M.; Bhortake, L.R. Formulation and evaluation of diclofenac sodium effervescent tablet. Infrared Spectroscopy., 2014, 9(10), 11.
[7]
Aslani, A.; Sharifian, T. Formulation, characterization and physicochemical evaluation of amoxicillin effervescent tablets. Adv. Biomed. Res., 2014, 3(1), 209.
[http://dx.doi.org/10.4103/2277-9175.143252] [PMID: 25371866]
[8]
Monton, C.; Suksaeree, J.; Pathompak, P. Can makjong (Scaphium macropodum) powder formed gel in effervescent blend. Int. J. Pharm. Pharm. Sci., 2014, 6(6), 610-612.
[9]
Aslani, A.; Fattahi, F. Formulation, characterization and physicochemical evaluation of potassium citrate effervescent tablets. Adv. Pharm. Bull., 2013, 3(1), 217-225.
[PMID: 24312839]
[10]
Kaushik, D.; Dureja, H.; Saini, T.R. Formulation and evaluation of olanzapine mouth dissolving tablets by effervescent formulation approach. INDIAN DRUGS-BOMBAY, 2004, 41, 410-412.
[11]
Bhattacharyya, S.; Swetha, G. Formulation and evaluation of effervescent granules of Fexofenadine hydrochloride. Pharma Innov., 2014, 3(3, Part A), 1.
[12]
Patel, J.B.; Suhagia, B.N.; Patel, M.N.; Patel, B.T.; Patel, A.M.; Patel, T.R. Preparation and evaluation of effervescent tablets of ibuprofen. WJPPS, 2013, 2(4), 2145-2155.
[13]
Patel, S.G.; Siddaiah, M. Formulation and evaluation of effervescent tablets: A review. J. Drug Deliv. Ther., 2018, 8(6), 296-303.
[http://dx.doi.org/10.22270/jddt.v8i6.2021]
[14]
Kumar, S.; Ashish, B. Formulation by Design Approach for Fizzy Granules Using Statistical Optimization Methodologies. Asian J. Pharm., 2015, 9(4), S59.
[15]
Banerjee, N.; Singh, S. Formulation, evaluation and optimization of effervescent granules to be reconstituted into suspension of levetiracetam for sustained release. Int. J. Pharm. Sci. Rev. Res., 2013, 20(2), 181-186.
[16]
Kim, W.S.; Han, G.G.; Hong, L.; Kang, S.K.; Shokouhimehr, M.; Choi, Y.J.; Cho, C.S. Novel production of natural bacteriocin via internalization of dextran nanoparticles into probiotics. Biomaterials, 2019, 218, 119360.
[http://dx.doi.org/10.1016/j.biomaterials.2019.119360] [PMID: 31336278]
[17]
Mousavi Khaneghah, A.; Abhari, K.; Eş, I.; Soares, M.B.; Oliveira, R.B.A.; Hosseini, H.; Rezaei, M.; Balthazar, C.F.; Silva, R.; Cruz, A.G.; Ranadheera, C.S.; Sant’Ana, A.S. Interactions between probiotics and pathogenic microorganisms in hosts and foods: A review. Trends Food Sci. Technol., 2020, 95, 205-218.
[http://dx.doi.org/10.1016/j.tifs.2019.11.022]
[18]
Mombelli, B.; Gismondo, M.R. The use of probiotics in medical practice. Int. J. Antimicrob. Agents, 2000, 16(4), 531-536.
[http://dx.doi.org/10.1016/S0924-8579(00)00322-8] [PMID: 11118874]
[19]
Sanders, M.E. Probiotics: considerations for human health. Nutr. Rev., 2003, 61(3), 91-99.
[http://dx.doi.org/10.1301/nr.2003.marr.91-99] [PMID: 12723641]
[20]
Arora, M.; Sharma, S.; Baldi, A. Comparative insight of regulatory guidelines for probiotics in USA, India and Malaysia: A critical review. Int. J. Biotechnol. Wellness Ind., 2013, 2(2), 51-64.
[21]
Doron, S.; Gorbach, S.L. Probiotics: their role in the treatment and prevention of disease. Expert Rev. Anti Infect. Ther., 2006, 4(2), 261-275.
[http://dx.doi.org/10.1586/14787210.4.2.261] [PMID: 16597207]
[22]
Teughels, W.; Van Essche, M.; Sliepen, I.; Quirynen, M. Probiotics and oral healthcare. Periodontol. 2000, 2008, 48(1), 111-147.
[http://dx.doi.org/10.1111/j.1600-0757.2008.00254.x] [PMID: 18715361]
[23]
Sen, M. Role of probiotics in health and disease: A review. J. Pak. Med. Assoc., 2013, 63(2), 253-257.
[24]
Hemaiswarya, S.; Raja, R.; Ravikumar, R.; Carvalho, I.S. Mechanism of action of probiotics. Braz. Arch. Biol. Technol., 2013, 56(1), 113-119.
[http://dx.doi.org/10.1590/S1516-89132013000100015]
[25]
Kerry, R.G.; Patra, J.K.; Gouda, S.; Park, Y.; Shin, H-S.; Das, G. Benefaction of probiotics for human health: A review. Yao Wu Shi Pin Fen Xi, 2018, 26(3), 927-939.
[PMID: 29976412]
[26]
Bhoop, B.S. Quality by Design (QbD) for holistic pharma excellence and regulatory compliance. Pharm. Times, 2014, 46(8), 26-33.
[27]
Sharma, S.; Arora, M.; Baldi, A. Probiotics in India: Current status and future prospects. Pharm Aspire., 2013, 1, 1-12.
[28]
Vogt, F.G.; Kord, A.S. Development of quality-by-design analytical methods. J. Pharm. Sci., 2011, 100(3), 797-812.
[http://dx.doi.org/10.1002/jps.22325] [PMID: 21280050]
[29]
Kovács, B.; Péterfi, O.; Kovács-Deák, B.; Székely-Szentmiklósi, I.; Fülöp, I.; Bába, L.I.; Boda, F. Quality-by-design in pharmaceutical development: From current perspectives to practical applications. Acta Pharm., 2021, 71(4), 497-526.
[http://dx.doi.org/10.2478/acph-2021-0039] [PMID: 36651549]
[30]
Hall, A. Experimental design: Design experimentation. Des. Issues, 2011, 27(2), 17-26.
[http://dx.doi.org/10.1162/DESI_a_00074-Hall]
[31]
Franceschini, G.; Macchietto, S. Model-based design of experiments for parameter precision: State of the art. Chem. Eng. Sci., 2008, 63(19), 4846-4872.
[http://dx.doi.org/10.1016/j.ces.2007.11.034]
[32]
Jain, S. Quality by design (QBD): A comprehensive understanding of implementation and challenges in pharmaceuticals development. Int. J. Pharm. Pharm. Sci., 2014, 6(1), 29-35.
[33]
Mishra, V.; Thakur, S.; Patil, A.; Shukla, A. Quality by design (QbD) approaches in current pharmaceutical set-up. Expert Opin. Drug Deliv., 2018, 15(8), 737-758.
[http://dx.doi.org/10.1080/17425247.2018.1504768] [PMID: 30044646]
[34]
Shivhare, M.; McCreath, G. Practical considerations for DoE implementation in quality by design. Bioprocess Int., 2010, 8(6), 22-30.
[35]
Thakor, N.S.; Amrutkar, S.V. Implementing quality by design (QbD) in chromatography. J Anal Pharm Chem., 2017, 4(1), 1078.
[36]
Agrawal, R; Naveen, Y. Pharmaceutical processing–A review on wet granulation technology. Int. J. Pharm. Front. Res., 2011, 1(1), 65-83.
[37]
Kristensen, H.G.; Schaefer, T. Granulation: A review on pharmaceutical wet-granulation. Drug Dev. Ind. Pharm., 1987, 13(4-5), 803-872.
[http://dx.doi.org/10.3109/03639048709105217]
[38]
Mesut, B.; Özsoy, Y.; Aksu, B. The place of drug product critical quality parameters in quality by design (QBD). Turkish J Pharm Sci., 2015, 12(1), 75-92.
[39]
Faisal, A.; Al-Absi, M.; Alagbarri, S.; Al-Nowihi, M. Formulation by design approach for effervescent granules of vitamin C using statistical optimization methodologies. J. Appl. Pharm. Res., 2020, 8(4), 62-69.
[http://dx.doi.org/10.18231/j.joapr.2020.v.8.i.4.62.69]
[40]
Karatzas, A.A.; Politis, S.N.; Rekkas, D.M. Development of rapidly dissolving pellets within the Quality by Design approach. Drug Dev. Ind. Pharm., 2017, 43(5), 770-779.
[http://dx.doi.org/10.1080/03639045.2016.1220576] [PMID: 27625003]
[41]
Jadav, M; Pal, V; Pandit, H; Suthar, N; Pithadia, A; Jha, LL Formulation, optimization and evaluation of nutraceutical effervescent granules containing curcumin and ascorbic acid by fusion technique using full factorial design. J. Nat. Remedies., 2023, 23(4), 1509-1516.
[42]
Teng, K.; Fu, H.; Wu, G.; Gong, P.; Xie, Y.; Zhou, P.; Gong, X.; Qu, H. QbD-Guided Traditional Chinese Medicine Manufacturing Process: Development and Optimization of Fluid-Bed Granulation and Drying Processes for Xiaochaihu Capsules. AAPS PharmSciTech, 2023, 24(7), 210.
[http://dx.doi.org/10.1208/s12249-023-02663-z] [PMID: 37821749]
[43]
Desai, N.; Purohit, R. Development of novel high density gastroretentive multiparticulate pulsatile tablet of clopidogrel bisulfate using quality by design approach. AAPS PharmSciTech, 2017, 18(8), 3208-3218.
[http://dx.doi.org/10.1208/s12249-017-0805-2] [PMID: 28550603]
[44]
Singh, L.; Sharma, V. Quality by Design (QbD) approach in pharmaceuticals: status, challenges and next steps. Drug Deliv. Lett., 2015, 5(1), 2-8.
[http://dx.doi.org/10.2174/2210303104666141112220253]
[45]
Walter, M.T.; Walter, M.F.; Brooks, E.S.; Steenhuis, T.S.; Boll, J.; Weiler, K. Hydrologically sensitive areas: Variable source area hydrology implications for water quality risk assessment. J. Soil Water Conserv., 2000, 55(3), 277-284.
[46]
Mayes, T. Risk analysis in HACCP: burden or benefit? Food Control, 1998, 9(2-3), 171-176.
[http://dx.doi.org/10.1016/S0956-7135(97)00055-8]
[47]
Notermans, S.; Mead, G.C. Incorporation of elements of quantitative risk analysis in the HACCP system. Int. J. Food Microbiol., 1996, 30(1-2), 157-173.
[http://dx.doi.org/10.1016/0168-1605(96)00997-X] [PMID: 8856381]
[48]
Charoo, N.A.; Ali, A.A. Quality risk management in pharmaceutical development. Drug Dev. Ind. Pharm., 2013, 39(7), 947-960.
[http://dx.doi.org/10.3109/03639045.2012.699065] [PMID: 22757979]
[49]
Bhoop, B.S.; Raza, K.; Beg, S. Developing “optimized” drug products employing “designed” experiments. Chemical Industry Digest., 2013, 23, 70-76.
[50]
Cundell, T. Microbial contamination risk assessment in non‐sterile drug product manufacturing and risk mitigation. In: Pharmaceutical Microbiological Quality Assurance and Control; Wiley, 2019.
[http://dx.doi.org/10.1002/9781119356196.ch2]
[51]
Khandke, S.S.; Mayes, T. HACCP implementation: A practical guide to the implementation of the HACCP plan. Food Control, 1998, 9(2-3), 103-109.
[http://dx.doi.org/10.1016/S0956-7135(97)00065-0]
[52]
Pazhayattil, A.B.; Sayeed-Desta, N.; Fredro-Kumbaradzi, E.; Collins, J. Solid Oral Dose Process Validation; Springer, 2018.
[http://dx.doi.org/10.1007/978-3-030-02472-7]
[53]
Hassan, H.; Adam, S.K.; Alias, E.; Meor Mohd Affandi, M.M.R.; Shamsuddin, A.F.; Basir, R. Central composite design for formulation and optimization of solid lipid nanoparticles to enhance oral bioavailability of acyclovir. Molecules, 2021, 26(18), 5432.
[http://dx.doi.org/10.3390/molecules26185432] [PMID: 34576904]
[54]
Pandya, V.M.; Patel, J.K.; Patel, D.J. Formulation and optimization of nanosuspensions for enhancing simvastatin dissolution using central composite design. Dissolut. Technol., 2011, 18(3), 40-45.
[http://dx.doi.org/10.14227/DT180311P40]
[55]
Pai, R.S.; Singh, G.; Devi, V.K. Response surface methodology and process optimization of sustained release pellets using Taguchi orthogonal array design and central composite design. J. Adv. Pharm. Technol. Res., 2012, 3(1), 30-40.
[http://dx.doi.org/10.4103/2231-4040.93565] [PMID: 22470891]
[56]
Vuppalapati, L.; Cherukuri, S.; Neeli, V.; Reddy Yeragamreddy, P.; Reddy Kesavan, B. Application of central composite design in optimization of valsartan nanosuspension to enhance its solubility and stability. Curr. Drug Deliv., 2016, 13(1), 143-157.
[http://dx.doi.org/10.2174/1567201812666150724094358] [PMID: 26205900]
[57]
Saroj, S.; Shah, P.; Jairaj, V.; Rathod, R. Green analytical chemistry and quality by design: A combined approach towards robust and sustainable modern analysis. Curr. Anal. Chem., 2018, 14(4), 367-381.
[http://dx.doi.org/10.2174/1573411013666170615140836]
[58]
Bansal, S.; Beg, S.; Garg, B.; Asthana, A.; Asthana, G.S.; Singh, B. QbD-oriented development and characterization of effervescent floating-bioadhesive tablets of cefuroxime axetil. AAPS PharmSciTech, 2016, 17(5), 1086-1099.
[http://dx.doi.org/10.1208/s12249-015-0431-9] [PMID: 26527606]
[59]
Keleb, E.; Vermeire, A.; Vervaet, C.; Remon, J.P. Twin screw granulation as a simple and efficient tool for continuous wet granulation. Int. J. Pharm., 2004, 273(1-2), 183-194.
[http://dx.doi.org/10.1016/j.ijpharm.2004.01.001] [PMID: 15010142]
[60]
Pronk, P.; Infante Ferreira, C.A.; Witkamp, G.J. A dynamic model of Ostwald ripening in ice suspensions. J. Cryst. Growth, 2005, 275(1-2), e1355-e1361.
[http://dx.doi.org/10.1016/j.jcrysgro.2004.11.173]
[61]
Sumit, K.; Shikha, T.; Deepika, T.; Ashish, B. A quantitative approach for pharmaceutical quality by design patterns. Inveti Rapid: Pharm Anal Qual Assur., 2012, 4, 1-8.
[62]
Naman, S.; Madhavi, N.; Singh, B.; Madan, J.; Baldi, A. Implementing risk-based quality by design for development and optimization of flavored oral disintegrating mini tablets. J. Drug Deliv. Sci. Technol., 2021, 66, 102799.
[http://dx.doi.org/10.1016/j.jddst.2021.102799]
[63]
Kumar, S.; Baldi, A. Design of experiment based statistical optimization in life science research: An overview. Pharm Aspire., 2013, 4, 35-43.
[64]
Quellet, C.; Schudel, M.; Ringgenberg, R. Flavors & fragrance delivery systems. Chimia (Aarau), 2001, 55(5), 421-428.
[http://dx.doi.org/10.2533/chimia.2001.421]
[65]
Chudiwal, V.S.; Shahi, S.; Chudiwal, S. Development of sustained release gastro-retentive tablet formulation of nicardipine hydrochloride using quality by design (QbD) approach. Drug Dev. Ind. Pharm., 2018, 44(5), 787-799.
[http://dx.doi.org/10.1080/03639045.2017.1413111] [PMID: 29198152]
[66]
Kharia, A.A.; Soni, P.; Barik, S. Controlled Release Formulation of Tofacitinib Citrate Tablets Evaluated Using Quality by Design (QBD) Approach. J. Pharm. Res. Int., 2021, •••, 290-306.
[67]
Mangwandi, C.; Adams, M.J.; Hounslow, M.J.; Salman, A.D. An investigation of the influence of process and formulation variables on mechanical properties of high shear granules using design of experiment. Int. J. Pharm., 2012, 427(2), 328-336.
[http://dx.doi.org/10.1016/j.ijpharm.2012.02.029] [PMID: 22391113]
[68]
Almutairy, B.K.; Khafagy, E.S.; Alalaiwe, A.; Aldawsari, M.F.; Alshahrani, S.M.; Alsulays, B.B.; Alshetaili, A.S.; Alshehri, S.M.; Fayed, M.H. Enhancing the poor flow and tableting problems of high drug-loading formulation of canagliflozin using continuous green granulation process and design-of-experiment approach. Pharmaceuticals (Basel), 2020, 13(12), 473.
[http://dx.doi.org/10.3390/ph13120473] [PMID: 33348779]
[69]
Mamidi, H.K.; Palekar, S.; Nukala, P.K.; Mishra, S.M.; Patki, M.; Fu, Y.; Supner, P.; Chauhan, G.; Patel, K. Process optimization of twin-screw melt granulation of fenofibrate using design of experiment (DoE). Int. J. Pharm., 2021, 593, 120101.
[http://dx.doi.org/10.1016/j.ijpharm.2020.120101] [PMID: 33309834]
[70]
Soylak, M.; Narin, I.; Bezerra, M.; Ferreira, S. Factorial design in the optimization of preconcentration procedure for lead determination by FAAS. Talanta, 2005, 65(4), 895-899.
[http://dx.doi.org/10.1016/j.talanta.2004.08.011] [PMID: 18969885]
[71]
Mahapatra, A.P.K.; Saraswat, R.; Botre, M.; Paul, B.; Prasad, N. Application of response surface methodology (RSM) in statistical optimization and pharmaceutical characterization of a patient compliance effervescent tablet formulation of an antiepileptic drug levetiracetam. Future Journal of Pharmaceutical Sciences, 2020, 6(1), 82.
[http://dx.doi.org/10.1186/s43094-020-00096-0]
[72]
Guideline, I.C.H.H.T. Pharmaceutical development Q8. Curr. Sep., 2005, 4, 11.
[73]
Arshad, M.S.; Sedhain, K.; Hussain, A.; Abbas, N.; Mudassir, J.; Mehmood, F.; Irfan, M.; Latif, S. Quantification of carbon dioxide released from effervescent granules as a predictor of formulation quality using modified Chittick apparatus. Trop. J. Pharm. Res., 2021, 18(3), 449-458.
[http://dx.doi.org/10.4314/tjpr.v18i3.1]
[74]
Rani, K.C.; Parfati, N.; Ekajayani, N.I.; Kurniawan, I.M.A.; Kristiani, N.P.W. The development of Moringa leaves effervescent granules with effervescent agent of citric acid and sodium bicarbonate. Pharmaciana, 2021, 11(2), 225-240.
[http://dx.doi.org/10.12928/pharmaciana.v11i2.20873]
[75]
Sreekanth, S.K.; Palanichamy, S.; Sekharan, T.R.; Thirupathi, A.T. TABLETS OF NIFEDIPINE. Int. J. Pharma Bio Sci., 2010, 1, 2.
[76]
Davis, BS Quality by design. In: Risk management applications in pharmaceutical and biopharmaceutical manufacturing; Wiley, 2013; pp. 89-100.
[http://dx.doi.org/10.1002/9781118514399.ch5]
[77]
J, AL-MOUSAWY Formulation and evaluation of effervescent granules of ibuprofen. Int J App Pharm., 2019, 11(6), 66-69.
[78]
Gupta, S; Kesarla, R; Omri, A Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. ISRN Pharm., 2013, 2013, 848043.
[http://dx.doi.org/10.1155/2013/848043]
[79]
2005.Harmonized tripartite guideline, validation of analytical procedures: text and methodology. Proceedings of the international conference on harmonization of technical requirements for registration of pharmaceuticals for human use,
[80]
Desai, S.R. Quality by design-based formulation and evaluation of fast dissolving tablet of aspirin. Asian J. Pharm., 2018, 12(01) [AJP].

Rights & Permissions Print Cite
Article Metrics
39
1
© 2026 Bentham Science Publishers | Privacy Policy